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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S301not all patients that receive HA injections have an optimal response.
Several different HA formulations are available and a comparative
analysis of outcomes is lacking in the literature. Therefore, the purpose
of this study was to quantify the functional beneﬁt of two different HA
formulations for individuals with knee OA.
Methods: The Knee Outcome Survey (KOS) and Global Rating Score
(GRS) from patients who received HA injections for knee OA were
analyzed. Patients with bilateral injections completed a questionnaire
for each limb. Baseline KOS and GRS scores prior to injection and scores
4-6 weeks after the last injectionwere compared between subjects who
received 5 Sodium Hyaluronate (Supartz) injections (n ¼ 226) or
a single Hylan G-F 20 (Synvisc-One) injection (n ¼ 368). "Responders"
to the HA injections were operationally deﬁned as 1) Patients who had
a KOS change score greater than 10 points or 2) Patients who showed
any increase in KOS scores. Self-reported knee function, ranked as
“Severely Abnormal”, “Abnormal”, “Nearly Normal”, or “Normal” was
evaluated at baseline to stratify groups if a signiﬁcant interaction effect
was found. “Normal” subjects were subjects without functional limi-
tations, but may have had pain or were known to have chondral lesions.
A repeated measures ANOVA was used to assess change in KOS score
between injection types and over time. Chi-square analysis was used to
determine differences in the responder rate between injection types
and determine if therewas a relationship between change perception of
function (KOS and GRS) and baseline self-reported knee function.
Results: 594 knees were assessed and time between ﬁrst injection and
follow-up was 78 +/- 13 days for patients who received Sodium Hya-
luronate and 46 +/- 15 days for patients who received Hylan G-F 20.
There was a signiﬁcant Self-Function by Time interaction effect
(p0.002) and those with lower reported self-functional score
(abnormal, severely abnormal) demonstrated greater improvement in
KOS and GRS scores at follow-up (Figures 1 and 2). There was no
Injection Type by Time interaction effect and no difference in responder
rates when stratiﬁed by injection type suggesting no difference in
outcomes between the multi or single injection (p>0.455). Most
patients patients demonstrated some improvement on the KOS at
follow-up, although a smaller number of individuals achieved a 10 point
change on the KOS (Table 1).
Conclusions:HA injections offer small, but signiﬁcant improvements in
self-reported function for the majority of patients with OA. There was
no additional functional beneﬁt to using one particular formulation.
Patients who report their knee function as abnormal or severely
abnormal at baseline are most likely to have a larger response at follow-
up. Future evaluations should assess pain and performance in addition
to self-perception outcomes.ĂĂ
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INTRA ARTICULAR DRUG DELIVERY THROUGH AN IN-SITU GELLING
SYSTEM
M.J. Sandker y, A. Petit z, P. de Bruin z, R. Meyboom z, M. Siebelt y, W.E.
Hennink x, H.H. Weinans y. yDept. of Orthopedic Surgery, Erasmus Med.
Ctr., Rotterdam, The Netherlands; z InGell Labs BV, Groningen, The
Netherlands; xDept. of Pharmaceutics, Utrecht Inst. for Pharmaceutical
Sci., Utrecht, The Netherlands
Purpose: Our aim was to develop a biodegradable, in situ forming gel
suitable for prolonged, i.e. several weeks, intra-articular drug delivery.
Gel degradation kinetics, visualization, drug release and intra-articular
biocompatibility were tested
Methods: Gel synthesis PCLA-PEG-PCLA synthesis was performed by
ring opening polymerization of L-lactide and ε-caprolactone in solution
using PEG1500-diol as macroinitiator and tin(II) 2-ethylhexanoate as
catalyst. To gain radiopacity, TIBO-capping of the PCLA-PEG-PCLA was
perfomed using an excess of TIBO chloride. In-vitro gel behavior Phos-
phate buffer was added to the polymer (25wt %) and the resulting gel
was kept at 37 C for the duration of the experiment. At predetermined
time points, residual gel weight was measured. In-vivo experiments
Group 1 (n¼6 male Wistar rats); 100ml radiopaque gel was injected
subcutaneous (n¼4) or in the knee joint (n¼2) and scanned regularly to
visualize in vivo gel degradation longitudinally. Attenuation and volume
of the gels were calculated. Group 2 (n¼10); 50 ml non-radiopaque gel
was injected in the left knee, the right knee served as a control (50ml
saline). mCT arthographies were acquired before injection, after 6 and 12
weeks to monitor cartilage quality (sGAG content is correlated inversely
to Hexabrix inﬂux) and quantity over time. After the last scan, knees
were harvested for histology. Group 3 (n¼5); 500 ml of Celecoxib loaded
gels (60 mg/g) were injected subcutaneously and blood samples were
taken regularly to analyze drug release with UPLC.
Results: In-vitro gel degradation Complete gel degradation tookw130-
140 days. Gel attenuation corresponded well with the measured poly-
mer concentration over time, proving that mCT is indeed a good tech-
nique to quantify the amount of polymer present. In-vivo experiments
Group 1: Total gel volume directly after subcutaneous injection by mCT
was set at 100% and for all following time points the percentage of
residual volume was calculated (ﬁgure 1). A controlled degradation was
observed for period of twelve weeks. Upon intra-articular injection, the
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of 4 weeks. Group 2: No changes in patellar cartilage quantity or quality
occurred following intra-articular gel injection (p>0.10). At t¼0;
t¼6weeks and t¼12weeks, cartilage volume L/R ratios were 1.020.12;
0.990.1; 1.08.04 respectively; for attenuation 1.040.09; 1.050.08;
1.030.13. Histology conﬁrmed that the gel did not affect the cartilage.
Group 3; sustained drug release from the gel was conﬁrmed with Cel-
ecoxib being detectable in plasma samples up to 40 days at a sustained
level of w50-100 ìg/l (ﬁgure 2).
Conclusions: Aliphatically-modiﬁed PCLA-PEG-PCLA form radiopaque
and biocompatible gels which are able to deliver encapsulated drugs
upon degradation over a period of several weeks. This system is
therefore a promising candidate for intra articular drug delivery as
a treatment for OA.
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SAFETY OF MULTIPLE MUSCULOSKELETAL INJECTIONS IN PATIENTS
TAKING WARFARIN OR WARFARIN AND ASPIRIN
S.P. Pandit y, J. Waterman z, J. Corriea x. yUniv. of Connecticut Hlth.Ctr.,
Farmington, CT, USA; zUniv. of Connecticut Sch. of Med. and the
Connecticut VA Hlth.care System, Farmington and Newington, CT, USA;
x The Connecticut VA Hlth.care System, Newington, CT, USA
Purpose: Injections involving the musculoskeletal system are
a common practice in rheumatology. Several studies have shown the
relative safety of single musculoskeletal injections (MSI) in patients
taking warfarin. This prospective study looked at repeated injections
regarding the ongoing safety of MSI in patients taking warfarin and also
in patients taking warfarin and low dose aspirin.
Methods: A total of 42 patients were entered into the study from 1/
2008 to 12/2010. There were a total of 216 injections. All patients who
had at least 2 MSI in any part of their musculoskeletal system and were
actively followed in the VA Anticoagulation Clinic were included in the
study. Patients who received only one MSI or had multiple injectionsbut were not followed by the VA Anticoagulation Clinic during the study
period were excluded. All of the patients were taking warfarin and 14
were also taking aspirin for a variety of causes. All patients were on
stable doses of warfarin and had INR levels within a month of the
injections. After receiving injections, all patients were contacted by
phone within a month of the injections, at the time of the INR check,
and directly asked if there had been any complications related to the
injections.
Results: Of the 216 injections in the 42 patients, the knee was the most
common joint injected (n¼ 91: 42.1%). Other sites of injections included
the shoulder (n ¼ 56: 25.9%); humeral epicondyle (n ¼ 6: 2.7%); small
hand joints (n ¼ 11: 5.1%); wrist (n ¼ 5: 2.3%); various bursae (n ¼ 14:
6.5%); other soft tissue sites (n ¼ 33: 15.2%) Injectates included corti-
costeroids (CS) and hyaluronate. CS injections were the most common
representing 81.8% of the total injections .The average total number of
injections per patient was 5.1. The mode was 2. INR levels ranged from
1.1 - 4.8; average INR: 2.5. Only two patients reported bruising at the
injection site. One patient was also taking aspirin. INRs in both patients
were 2.1 and 2.4. No other complications were reported and no added
complications in the patients taking both warfarin and aspirin.
Conclusions: It has been shown that single MSI are safe in patients on
warfarin. This study demonstrates that repeated injections in any site in
the musculoskeletal system are also safe in patients on warfarin and
patients on warfarin and aspirin.590
AN INNOVATIVE HYALURONIC ACID PRODUCT FOR
VISCOSUPPLEMENTATION IN PATIENTS WITH OSTEOARTHRITIS
S. Gavard. Anteis, Meyrin, Switzerland
Purpose: The speciﬁc formulation [HA+sorbitol] of Synolis V-A is
based on a high molecular weight of HA (> 2 MDa in the ﬁnal sterilized
gel) from non animal origin, with a high HA concentration (20 mg/ml),
combined with a high concentration of a free radical scavenger, the
sorbitol (40 mg/ml). The aims of this study are to evaluate the
mechanical/rheological properties and the resistance to free radicals
degradation of Synolis V-A.
Methods: The rheological properties are analyzed by frequency sweep
experiments at 25C thanks to a parallel plate rheometer (AR2000, TA
Instruments). The resistance to free radical degradation is observed
visually by adding an oxidant agent (H2O2) on the viscosupplement
(Weight of H2O2 ¼ 1/15 x Weight of viscosupplement), by heating the
mixing at 60C and by watching the ﬂow of the product over time. The
resistance to free radical degradation is also followed thanks to an
AR2000 rheometer (time sweep experiments at 37C). Results of
resistance to degradation obtained with Synolis V-A are compared to 5
other commercial viscosupplements.
Results: Visco-elastic properties of Synolis V-A. Synolis V-A is charac-
terized by a visco-elastic behavior close to the human synovial ﬂuid
(viscous and elastic moduli crossing at 0.4 Hz) and high viscous and
elastic moduli due to the high afﬁnity between HA and sorbitol that
stabilizes the structure through a very dense network of hydrogen
bonds. Resistance to free radical degradation. In presence of free radi-
cals (H2O2), Synolis V-A demonstrates a much higher resistance against
free radicals than the other commercial viscosupplements as shown by
the visual observation and by the rheological properties.
Conclusions: Synolis V-A is an innovative viscosupplement made of
hyaluronic acid and sorbitol. Due to its patented formulation and
manufacturing process, Synolis V-A has outstanding rheological prop-
erties and a high resistance against in vivo degradation in the joint. As
demonstrated by several experiments, Synolis V-A is characterized by
a visco-elastic behaviour close to the human synovial ﬂuid, a very high
elasticity and viscosity and a high resistance to free radical degradation.
The synergetic combination of HA of high molecular weight and
sorbitol, combined with a speciﬁc manufacturing process which
included a ﬁnal moist heat sterilization, allows to obtain unique prop-
erties. Moreover, due to the high afﬁnity between HA and sorbitol,
Synolis V-A is stabilized through a very dense network of hydrogen
bonds. This complex structure of gel presents remarkably high visco-
elastic properties. Consequently, thanks to these particular visco-elastic
properties, Synolis V-A has a high ability to lubricate joints and to
absorb shocks, as with a healthy synovial ﬂuid. On the other hand, the
high ability of sorbitol to scavenge and neutralize free radicals (¼
antioxidant effect) allows to limit the degradation of the gel in order to
increase the half-life of the product in the joint (as described in the
